Zhejiang Orient Gene Biotech Co., Ltd (SHA:688298)
China · Delayed Price · Currency is CNY 21.80
-0.58 (-2.59%)
May 21, 2026, 3:00 PM CST
SHA:688298 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -575.8 | -597.41 | -529.02 | -397.58 | 2,068 | 4,920 |
Depreciation & Amortization | 195.67 | 195.67 | 204.24 | 165.49 | 86.56 | 37.31 |
Other Amortization | 23.61 | 23.61 | 24.12 | 18 | 8.51 | 2.27 |
Loss (Gain) From Sale of Assets | -1.75 | -1.75 | -0.99 | 0.18 | 0.01 | -0.01 |
Asset Writedown & Restructuring Costs | 201.04 | 201.04 | 81.75 | 63.86 | 366.58 | 0.05 |
Loss (Gain) From Sale of Investments | -8.68 | -8.68 | -24.6 | -48.85 | -7.66 | -11.22 |
Provision & Write-off of Bad Debts | - | - | 30.1 | 30.17 | -6.44 | 32.55 |
Other Operating Activities | 26.45 | 22.88 | -8.24 | 96.57 | 378.84 | 109.18 |
Change in Accounts Receivable | -71.21 | -71.21 | -109.37 | 210.28 | 825.4 | -692.05 |
Change in Inventory | -26.63 | -26.63 | 1.91 | -86.23 | -775.13 | -98.7 |
Change in Accounts Payable | 56.4 | 56.4 | -11.52 | -1,670 | 172.34 | 928.52 |
Change in Other Net Operating Assets | - | - | 15.78 | - | - | - |
Operating Cash Flow | -168.72 | -193.9 | -348.33 | -1,646 | 2,996 | 5,204 |
Operating Cash Flow Growth | - | - | - | - | -42.43% | 190.67% |
Capital Expenditures | -287.79 | -307.67 | -924.09 | -996.05 | -1,052 | -507.87 |
Sale of Property, Plant & Equipment | 2.57 | 2.62 | 7.51 | 0.81 | 2.58 | 1.79 |
Cash Acquisitions | - | - | -320.76 | -78.52 | -184.87 | -43.71 |
Investment in Securities | 151.87 | 49.54 | 678.26 | 81.54 | -1,076 | 228.15 |
Other Investing Activities | 283.2 | 833.12 | -111.06 | -1,126 | -65.22 | - |
Investing Cash Flow | 149.85 | 577.6 | -670.15 | -2,118 | -2,376 | -321.64 |
Long-Term Debt Issued | - | 384 | 300.75 | 772 | 50 | - |
Total Debt Issued | 209.12 | 384 | 300.75 | 772 | 50 | - |
Long-Term Debt Repaid | - | -510.06 | -459.27 | -331.82 | -6.21 | -6.97 |
Total Debt Repaid | -207.06 | -510.06 | -459.27 | -331.82 | -6.21 | -6.97 |
Net Debt Issued (Repaid) | 2.06 | -126.06 | -158.52 | 440.18 | 43.79 | -6.97 |
Repurchase of Common Stock | - | - | -276.95 | - | - | - |
Common Dividends Paid | -5.94 | -6.71 | -16.63 | -351.14 | -742.04 | -504.67 |
Other Financing Activities | -72.08 | -101.11 | 0.36 | -39.51 | - | 2.47 |
Financing Cash Flow | -75.96 | -233.88 | -451.74 | 49.54 | -698.25 | -509.17 |
Foreign Exchange Rate Adjustments | -52.62 | -24.41 | 51.89 | 85.85 | 536.65 | -75.44 |
Net Cash Flow | -147.45 | 125.41 | -1,418 | -3,628 | 458.62 | 4,298 |
Free Cash Flow | -456.51 | -501.57 | -1,272 | -2,642 | 1,944 | 4,696 |
Free Cash Flow Growth | - | - | - | - | -58.60% | 182.32% |
Free Cash Flow Margin | -45.12% | -52.94% | -153.69% | -322.09% | 22.17% | 46.18% |
Free Cash Flow Per Share | -2.41 | -2.61 | -6.47 | -13.09 | 9.64 | 23.29 |
Cash Income Tax Paid | - | -5.48 | -13.59 | -24.31 | 1,112 | 260.08 |
Levered Free Cash Flow | -422.76 | -433.95 | -1,255 | -2,379 | 1,513 | 3,361 |
Unlevered Free Cash Flow | -422.76 | -433.95 | -1,243 | -2,368 | 1,517 | 3,362 |
Change in Working Capital | -29.27 | -29.27 | -125.68 | -1,573 | 101.82 | 113.54 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.